​
​

Mind Medicine (MindMed) (MNMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MNMD Stock Forecast

Mind Medicine (MindMed) stock forecast is as follows: an average price target of $18.67 (represents a 172.95% upside from MNMD’s last price of $6.84) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

MNMD Price Target

The average price target for Mind Medicine (MindMed) (MNMD) is $18.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $14.00. This represents a potential 172.95% upside from MNMD's last price of $6.84.

MNMD Analyst Ratings

Buy

According to 3 Wall Street analysts, Mind Medicine (MindMed)'s rating consensus is 'Buy'. The analyst rating breakdown for MNMD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Mind Medicine (MindMed) Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2024Sumart KulkamiCanaccord Genuity$14.00$6.45117.05%104.68%
Jun 05, 2024Brian AbrahamsRBC Capital$22.00$8.25166.67%221.64%
May 13, 2024Francois BriseboisOppenheimer$20.00$8.61132.42%192.40%
Nov 16, 2022-RBC Capital$5.00$2.8674.83%-26.90%
Row per page
Go to

The latest Mind Medicine (MindMed) stock forecast, released on Sep 16, 2024 by Sumart Kulkami from Canaccord Genuity, set a price target of $14.00, which represents a 117.05% increase from the stock price at the time of the forecast ($6.45), and a 104.68% increase from MNMD last price ($6.84).

Mind Medicine (MindMed) Price Target by Period

1M3M12M
# Anlaysts-13
Avg Price Target-$14.00$18.67
Last Closing Price$6.84$6.84$6.84
Upside/Downside-100.00%104.68%172.95%

In the current month, the average price target of Mind Medicine (MindMed) stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mind Medicine (MindMed)'s last price of $6.84. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024Canaccord GenuityBuyBuyHold
Jun 05, 2024RBC CapitalOutperformOutperformHold
May 13, 2024OppenheimerOutperformOutperformHold
Nov 16, 2022RBC Capital-OutperformInitialise
Aug 26, 2022Oppenheimer-OutperformInitialise
Row per page
Go to

Mind Medicine (MindMed)'s last stock rating was published by Canaccord Genuity on Sep 16, 2024. The company gave MNMD a "Buy" rating, the same as its previous rate.

Mind Medicine (MindMed) Financial Forecast

Mind Medicine (MindMed) Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Mind Medicine (MindMed)'s average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MNMD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Mind Medicine (MindMed) EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict MNMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mind Medicine (MindMed)'s previous annual EBITDA (undefined) of $NaN.

Mind Medicine (MindMed) Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-26.48M$-28.89M$-27.76M$-27.28M$-24.63M$-22.23M$-23.52M
High Forecast$-26.48M$-28.89M$-27.76M$-27.28M$-23.14M$-22.23M$-23.52M
Low Forecast$-26.48M$-28.89M$-27.76M$-28.08M$-25.38M$-22.23M$-23.52M
Surprise %-------

Mind Medicine (MindMed)'s average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MNMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Mind Medicine (MindMed) SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Mind Medicine (MindMed)'s average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MNMD last annual SG&A of $NaN (undefined).

Mind Medicine (MindMed) EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.33$-0.36$-0.35$-0.34$-0.31$-0.28$-0.33
High Forecast$-0.33$-0.36$-0.35$-0.34$-0.29$-0.28$-0.33
Low Forecast$-0.33$-0.36$-0.35$-0.35$-0.32$-0.28$-0.33
Surprise %-------

According to undefined Wall Street analysts, Mind Medicine (MindMed)'s projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MNMD previous annual EPS of $NaN (undefined).

Mind Medicine (MindMed) Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
RVPHReviva Pharmaceuticals$1.27$10.00687.40%Buy
CKPTCheckpoint Therapeutics$3.30$20.00506.06%Buy
KODKodiak Sciences$5.66$31.60458.30%Buy
MOLNMolecular Partners$5.83$29.00397.43%Buy
ITOSiTeos Therapeutics$7.88$37.67378.05%Buy
OPTOpthea$3.26$14.00329.45%Buy
ATAIAtai Life Sciences$1.67$6.00259.28%Buy
GHRSGH Research$9.47$28.00195.67%Buy
MNMDMind Medicine (MindMed)$6.84$18.67172.95%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
EWTXEdgewise Therapeutics$30.79$45.0046.15%Buy

MNMD Forecast FAQ

Is Mind Medicine (MindMed) a good buy?

Yes, according to 3 Wall Street analysts, Mind Medicine (MindMed) (MNMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of MNMD's total ratings.

What is MNMD's price target?

Mind Medicine (MindMed) (MNMD) average price target is $18.67 with a range of $14 to $22, implying a 172.95% from its last price of $6.84. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Mind Medicine (MindMed) stock go up soon?

According to Wall Street analysts' prediction for MNMD stock, the company can go up by 172.95% (from the last price of $6.84 to the average price target of $18.67), up by 221.64% based on the highest stock price target, and up by 104.68% based on the lowest stock price target.

Can Mind Medicine (MindMed) stock reach $10?

MNMD's average twelve months analyst stock price target of $18.67 supports the claim that Mind Medicine (MindMed) can reach $10 in the near future.

What are Mind Medicine (MindMed)'s analysts' financial forecasts?

Mind Medicine (MindMed)'s analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-70.375M (high $-68.881M, low $-71.121M), average SG&A $0 (high $0, low $0), and average EPS is $-0.911 (high $-0.892, low $-0.92). MNMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-110M (high $-110M, low $-111M), average SG&A $0 (high $0, low $0), and average EPS is $-1.376 (high $-1.376, low $-1.386).